SBP solbec pharmaceuticals limited

govt grant

  1. 3,176 Posts.
    Solbec Pharmaceuticals (SBP) today announced that it has secured
    funding from the Federal Government's Biotechnology Innovation Fund
    to develop research on its lead anti-cancer drug SBP002.

    SBP002, a novel glycoalkaloid has, in numerous tests, indicated
    powerful properties in fighting many cancers including malignant
    mesothelioma (MM), a cancer for which no effective treatment is
    currently available.

    Stephen Carter, Managing Director of Solbec Pharmaceuticals says:

    'Most cancer therapies seek either to eliminate tumours, or provide
    some form of immunisation. All our early data shows that SBP002 may
    succeed at both, while protecting patients from the side-effects
    usually associated with cancer treatment. This funding will enable us
    to advance our knowledge on the ability of SBP002 to prime the immune
    system with the support of our colleagues at the University of
    Western Australia

    Solbec Pharmaceuticals' science team is led by Dr Richard Lake,
    Research Fellow and Adjunct Senior Lecturer at University of Western
    Australia (UWA). Professor Bruce Robinson, Professor of Medicine at
    UWA is providing substantial intellectual input into the project.

    The Biotechnology Innovation Fund will fund half the $393,768
    project. Trial results are expected in September 2004.

    For more information please contact:

    Stephen Carter 08 9446 7555
    MANAGING DIRECTOR, Solbec Pharmaceuticals 0412 154 029

    David Michie 08 9381 4494
    MEDIA RELATIONS 0411 453 404

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.